Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 6/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.42 |
| ▸ | CLPP | Q16740 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | TCF4 | P15884 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037724 | 0.90 | CLPP (0.52) | CLPPCYP3A4TCF4CTNNB1CREBBP | |
| SCHEMBL12037883 | 0.90 | CLPP (0.39) | CACNA1GCACNA1HCACNA1ICLPPCYP3A4 | |
| SCHEMBL12037722 | 0.89 | CLPP (0.46) | CLPPCYP3A4 | |
| SCHEMBL14619993 | 0.89 | CLPP (0.44) | CLPPCYP3A4TCF4CTNNB1CREBBP | |
| SCHEMBL12037884 | 0.88 | CLPP (0.45) | CLPPCYP3A4TCF4CTNNB1CREBBP | |
| SCHEMBL12037712 | 0.88 | CLPP (0.55) | CLPPCYP3A4TCF4CTNNB1CREBBP | |
| SCHEMBL12037881 | 0.87 | CLPP (0.44) | CLPPCYP3A4 | |
| SCHEMBL12037888 | 0.87 | CLPP (0.56) | CLPP | |
| SCHEMBL12037880 | 0.86 | CLPP (0.56) | CLPPCYP3A4 | |
| SCHEMBL14629403 | 0.86 | CLPP (0.48) | CLPPCYP3A4TCF4CTNNB1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CACNA1G 4620/4885CACNA1H 4542/4885CACNA1I 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.